学術雑誌論文 Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis

Takeuchi, Tsutomu  ,  Yamamoto, Kazuhiko  ,  Yamanaka, Hisashi  ,  Ishiguro, Naoki  ,  Tanaka, Yoshiya  ,  Eguchi, Katsumi  ,  Watanabe, Akira  ,  Origasa, Hideki  ,  Kobayashi, Mariko  ,  Shoji, Toshiharu  ,  Togo, Osamu  ,  Miyasaka, Nobuyuki  ,  Koike, Takao

26 ( 4 )  , pp.473 - 480 , 2016 , Taylor & Francis
ISSN:1439-7595
NII書誌ID(NCID):AA1157187X
内容記述
Objectives: To compare the efficacy and safety of certolizumab pegol (CZP) with and without loading dose (LD) in a post-hoc analysis of two Japanese clinical studies. Methods: Data from the double-blind trials (DBT) J-RAPID and HIKARI, and their open-label extension (OLE) studies, were used. Patients randomized to CZP 200 mg every 2 weeks (Q2W) groups starting with LD (400 mg Weeks 0/2/4; LD group; J-RAPID: n = 82, HIKARI: n = 116) and patients randomized to placebo groups who subsequently started CZP Q2W without LD in the OLEs (No-LD group; J-RAPID: n = 61, HIKARI: n = 99) were analyzed. Efficacy and pharmacokinetics were assessed during 24 weeks. Adverse events were reported from all studies. Results: In both trials, the LD groups showed more rapid initial ACR20/50/70 kinetics, and maintained higher ACR50/70 responses until 24 weeks, compared with the No-LD groups. Anti-CZP antibody development was less frequent in the LD groups (J-RAPID: 1.2% versus 4.9%; HIKARI: 17.2% versus 27.3%). Similar safety profiles were reported between LD and No-LD groups (any AEs: 281.8 versus 315.7 [J-RAPID], 282.6 versus 321.3 [HIKARI] [incidence rate/100 patient-years]). Conclusions: Despite limitations, including comparing DBT and OLE studies, these results suggest that a CZP LD improves clinical response in active rheumatoid arthritis without altering the safety profile.

このアイテムのアクセス数:  回

その他の情報